Dr. Chauhan on Key Recent Advances in Neuroendocrine Tumors

Video

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors (NETs), and points to the future with ongoing combination studies.

Advances across oncology over recent years are finally beginning to trickle down into more rare tumor types, such as NETs, which generally lag behind in drug developments, Chauhan explains. More clinical trials are being conducted in NETs as well, he added.

Two examples of such studies include combination studies that Chauhan is an investigator of. These include a phase 2 study that is evaluating the combination of telotristat ethyl (Xermelo) and Lutathera (lutetium Lu 177 dotatate) in patients with well-differentiated NETs. Moreover, Chauhan is also excited about a phase 1 trial of triapine and Lutathera combined as a treatment for patients with well-differentiated somatostatin receptor-positive gastroenteropancreatic NETs.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine